LiveWire Group (LVWR) : 4-year performance

 

LiveWire Group went public on September 27, 2022, via a $1.8 billion

 merger with a special-purpose acquisition company (SPAC). 

• The company, formerly a Harley-Davidson electric motorcycle division, was spun off from its parent and became publicly traded on the New York Stock Exchange. 
• It is the first publicly traded electric motorcycle company in the United States.
• Ticker symbol: LVWR

 

 

 

Harley-Davidson spun off its electric motorcycle division, LiveWire, in a SPAC deal creating the first publicly traded electric motorcycle company in the United States.
 

VersaBank (VBNK) : 4-year performance

VersaBank is a Canadian chartered bank headquartered in London, Ontario. Formerly known as the Pacific & Western Bank of Canada, it was founded as a trust company in Saskatoon, Saskatchewan, in 1980 and later moved its head offices to London, Ontario.

• Founded 1980
• Headquarters London, Ontario, Canada
• Website versabank.com
• Employees 13

IPO: September 22, 2021

It priced its initial public offering (IPO) of 5.5 million common shares at US$10.00 per share (approximately CAD$12.80).

 

 

VersaBank has also said it plans to launch a digital currency known as VCAD. It will be represented one-to-one with the Canadian dollar and be the first digital currency to represent a fiat currency, and the first to be issued and backed by deposits of a North American bank.

VersaBank will work with several organizations to launch VCAD, including Stablecorp, Canada crypto manager 3iQ, and Mavennet, a Canadian leader in blockchain development.

Climb Bio (CLYM) : 4-year performance

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 28
Incorporated in 2018 
Headquartered in Wellesley Hills, Massachusetts
https://climbbio.com

RA Capital exchange agreement ignited multi-day rally extending into 27% gain today.

• The stock's sharp rise stems from a December 11, 2025, exchange agreement with RA Capital Management, where the investor swapped 20.44 million common shares for pre-funded warrants exercisable at a nominal price, signaling strong backing without immediate dilution. This filing, reported via SEC Form 8-K, triggered a 30.43% jump on December 12, with momentum building over subsequent days amid high volume exceeding 8 million shares. Today's movement amplifies this, as traders react to the deal's implications for sustained funding through 2027 and upcoming 2026 clinical readouts for budoprutug and CLYM116 in immune diseases, per recent analyst coverage. No new filings emerged today, but the prior event's positive sentiment persists.

Confluent (CFLT) : 4-year performance

Confluent, Inc. engages in creating a data infrastructure platform focused on data in motion. The firm provides application architecture engagement, multi data center, security and upgrade engagement, and Amazon web services cloud deployment services. Its products include Confluent Cloud, Confluent Platform, WarpStream BYOC, Connectors, Flink, Stream Governance, and Confluent Hub. 

The company was formerly known as Infinitem, Inc. and changed its name to Confluent, Inc. in September 2014. 

• Founded by Edward Jay Kreps, Neha Narkhede, and Jun Rao in 2014
• Headquartered in Mountain View, California
• Sector: Technology
• Industry: Software - Infrastructure
• Full Time Employees: 3,060
• Website:  confluent.io
• Ticker: CFLT

 

Kymera Therapeutics (KYMR) : atopic dermatitis potential matches Sanofi/Regeneron's blockbuster Dupixent in early biomarker response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.

The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 208
• Founded by Bruce Lee Booth and Nello Mainolfi in September 2015 
• Headquartered in Watertown, Massachusetts
• https://www.kymeratx.com

IPO: Aug 21, 20

 

 

 

 

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. 

European Wax Center (EWCZ) : 4-year performance

May 2026: an all-cash (approx. $330 million) acquisition by the private equity firm General Atlantic.  The stock ceased trading and was officially delisted from the Nasdaq Stock Market on May 8, 2026.

European Wax Center, Inc. operates as the franchisor and operator of out-of-home waxing services in the United States. It offers body and facial waxing services; and pre- and post-service products, including ingrown hair serums, exfoliating gels, brow shapers, and skin treatments, as well as skincare retail products. 

Q1 2025: 1,067 centers in 45 states.

• Sector: Consumer Defensive
• Industry: Household & Personal Products
• Full Time Employees: 124
• Founded in 2004 
• Headquartered in Plano, Texas
• https://waxcenter.com

IPO: August 5, 2021

Ticker: EWCZ

 

Regencell Bioscience (RGC) : 4-year performance

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder and autism spectrum disorder. 

• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic
• Full Time Employees: 12
• Incorporated in 2014 
• Headquartered in Causeway Bay, Hong Kong
• https://www.regencellbioscience.com

IPO: July 16, 2021

 

 

Tuya (TUYA) : 4-year performance

Tuya, Inc. engages in developing smart cloud service and IoT-related software and hardware solutions. It specializes in product, protocol, region, and supplier agnostics. The company was .

• Sector: Technology
• Industry: Software - Infrastructure
• Full Time Employees: 1,450
• Founded by Liao Han Chen, Alex Yang, Ruixin Zhou, and Xue Ji Wang on June 16, 2014 
• Headquartered in Hangzhou, China
• https://www.tuya.com

Ticker: TUYA

 

 

 

 

 

 

IPO March 18, 2021

Absci (ABSI) : 4-year performance

 

 

Crown Electrokinetics (CRKN) : 4-year performance

Crown Electrokinetics Corp. develops and sells optical switching films in the United States. 

The company was formerly known as 3D Nanocolor Corp. and changed its name to Crown Electrokinetics Corp. in October 2017.

• Sector: Basic Materials
• Industry: Specialty Chemicals
• Full Time Employees: 42
• Incorporated in 2015 
• Based in Corvallis, Oregon
• https://www.crownek.com

Crown Electrokinetics (CRKN) went public on January 26, 2021.

 

908 Devices (MASS) : 4-year performance

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 230
• Incorporated in 2012 
• Headquartered in Boston, Massachusetts
• Website www.908devices.com

 

 

 

 

Grid Dynamics (GDYN) to join the S&P SmallCap 600, replacing Revelyst Inc. (NYSE: GEAR)

Grid Dynamics (GDYN) bean trading on the Nasdaq Stock Market on March 6, 2020 after business combination with ChaSerg Technology Acquisition Corp. (Nasdaq: CTAC)

• Sector: Technology
• Industry: Information Technology Services
• Full Time Employees: 4,298
• Founded in 2006 
• Headquartered in San Ramon, California
• https://www.griddynamics.com

 

 

Repare Therapeutics (RPTX) : 4-year performance

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. 

The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 129
• Incorporated in 2016 
• Headquartered in Montreal, Canada
• The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University.
• https://www.reparerx.com

On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.

As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial.

Across all tumor types treated at the optimized RP2D (n=67), Lunre+Camo therapy showed a favorable and differentiated tolerability profile compared to current and emerging therapies.

The most common adverse event was anemia (26.9%, Grade 3).

Vertex (VERX) : 4-year performance

Vertex, Inc. engages in the provision of tax compliance software solutions.

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 1,500
• Founded in 1978 
• Headquartered in King of Prussia, Pennsylvania.
• https://www.vertexinc.com

Ticker:  VERX